[MO29] Mini-Oral Session 29　Lung Cancer / Thoracic Cancer 4（EGFR-TKI 1）
【E】

[MO29-6] Genomic profiles and potential determinants of response and resistance to sotorasib in KRAS p.G12C-mutated NSCLC

^○Toshiaki Takahashi¹, Ferdinandos Skoulidis², Martin Schuler³, Jürgen Wolf⁴, Fabrice Barlesi⁵, Timothy J. Price⁶, Grace K. Dy⁷, Ramaswamy Govindan⁸, Hossein Borghaei⁹, Gerald Falchook¹⁰, Bob T. Li¹¹, Suresh Ramalingam¹², Adrian Sacher¹³, Alexander Spira¹⁴, Abraham Anderson¹⁵, Agnes Ang¹⁵, Tian Dai¹⁵, Donna Flesher¹⁵, Paul Cifuentes¹⁵, Vamsidhar Velcheti¹⁶ (1.Division of Thoracic Oncology, Shizuoka Cancer Center, 2.University of Texas M.D. Anderson Cancer Center, 3.West German Cancer Center, University Hospital Essen, 4.University Hospital Cologne, 5.Gustave Roussy Institute, 6.Queen Elizabeth Hospital and University of Adelaide, 7.Roswell Park Cancer Institute, 8.Alvin J. Siteman Cancer Center, Washington University School of Medicine, 9.Fox Chase Cancer Center, 10.Sarah Cannon Research Institute, 11.Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, 12.Winship Cancer Institute, Emory University School of Medicine, 13.Princess Margaret Cancer Centre, 14.Virginia Cancer Specialists and Johns Hopkins University, 15.Amgen Inc, 16.Perlmutter Cancer Center, NYU Langone)